REGENERATIVE medicine firm Orthocell is seeking to raise $8 million to list on the Australian Securities Exchange (ASX).

Orthocell develops treatments for tendon, cartilage and soft tissue injuries, using a patient's own stem cells to repair the damage.

It is also developing a collagen-based product called CelGro, which provides mechanical strength to facilitate tissue repair.

"Musculoskeletal conditions are the most common reason to access health care services and costs Australia more than $4 billion each year," Orthocell chief executive Paul Anderson said in a statement on Thursday.

"Regenerative medicine aims to address these conditions by repairing and regenerating damaged tissue using the body's own building blocks in a more effective manner than ever before."

The company is offering 20 million shares at 40 cents per share.

The funds will be used to complete the development of CelGro and lodge it for regulatory approval in Australia.

Money will also go towards maintaining the regulatory approvals for the Ortho-ATI and Ortho-ACI stem cell treatments in Australia.

Orthocell will also use some for the funds to prepare for regulatory approval of Ortho-ATI in its first international market, which is likely to be either Europe or Japan.

The company says it has treated more than 400 patients, using the stem-cell treatments and is generating revenue from the treatments in Australia.

Continue reading here:
Orthocell to list on ASX